Fezolinetant impact on health‐related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials

Author:

Cano Antonio1ORCID,Nappi Rossella E.23,Santoro Nanette4,Stute Petra5,Blogg Martin6,English Marci L.7,Morga Antonia6,Scrine Ludmila6,Siddiqui Emad6,Ottery Faith D.7

Affiliation:

1. Department of Paediatrics, Obstetrics and Gynaecology, INCLIVA University of Valencia Valencia Spain

2. Department of Clinical, Surgical, Diagnostic and Paediatric Sciences University of Pavia Pavia Italy

3. Research Centre for Reproductive Medicine and Gynaecological Endocrinology – Menopause Unit Fondazione Policlinico IRCCS S. Matteo Pavia Italy

4. University of Colorado School of Medicine Aurora Colorado USA

5. Department of Obstetrics and Gynaecology, Inselspital Bern Switzerland

6. Astellas Pharma Europe Ltd Addlestone UK

7. Astellas Pharma Global Development Northbrook Illinois USA

Abstract

AbstractObjectiveTo assess the effect of fezolinetant treatment on health‐related quality of life using pooled data from SKYLIGHT 1 and 2 studies.DesignPrespecified pooled analysis.SettingUSA, Canada, Europe; 2019–2021.Population1022 women aged ≥40 to ≤65 years with moderate‐to‐severe vasomotor symptoms (VMS; minimum average seven hot flushes/day), seeking treatment for VMS.MethodsWomen were randomised to 12‐week double‐blind treatment with once‐daily placebo or fezolinetant 30 or 45 mg. Completers entered a 40‐week, active extension (those receiving fezolinetant continued that dose; those receiving placebo re‐randomised to fezolinetant received 30 or 45 mg).Main outcome measuresMean changes from baseline to weeks 4 and 12 on Menopause‐Specific Quality of Life (MENQoL) total and domain scores, Work Productivity and Activity Impairment questionnaire specific to VMS (WPAI‐VMS) domain scores, Patient Global Impression of Change in VMS (PGI‐C VMS); percentages achieving PGI‐C VMS of ‘much better’ (PGI‐C VMS responders). Mean reduction was estimated using mixed model repeated measures analysis of covariance.ResultsFezolinetant 45 mg mean reduction over placebo in MENQoL total score was −0.57 (95% confidence interval [CI] −0.75 to −0.39) at week 4 and −0.47 (95% CI −0.66 to −0.28) at week 12. Reductions were similar for 30 mg. MENQoL domain scores were also reduced and WPAI‐VMS scores improved. Twice as many women receiving fezolinetant reported VMS were ‘much better’ than placebo based on PGI‐C VMS assessment.ConclusionsFezolinetant treatment was associated with improvement in overall QoL, measured by MENQoL, and work productivity, measured by WPAI‐VMS. A high proportion receiving fezolinetant felt VMS were ‘much better’ based on PGI‐C VMS responder analysis.

Publisher

Wiley

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3